Evidence map›Paper›PMID 39983850›Full record

ReviewBiochemical pharmacology2025

The Janus-facedness of the aryl hydrocarbon receptor pathway Report of the 6th International AHR Meeting: Research, Prevention, Therapy.

Thomas Haarmann-Stemmann, Doreen Reichert, Xavier Coumoul, B Paige Lawrence, Gary H Perdew, David H Sherr, Heike Weighardt, Katharina M Rolfes, Charlotte Esser

Abstract readReview
In one paragraph

Review in Biochemical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas Haarmann-StemmannIUF - Leibniz Research Institute for Environmental Medicine Auf́m Hennekamp, 50 40225 Düsseldorf Germany. Electronic address: thomas.haarmann-stemmann@iuf-duesseldorf.de.
Doreen ReichertIUF - Leibniz Research Institute for Environmental Medicine Auf́m Hennekamp, 50 40225 Düsseldorf Germany.
Xavier CoumoulUniversité Paris Cité, INSERM, Health & Functional Exposomics - HealthFex, 75006 Paris, France.
B Paige LawrenceUniversity of Rochester Medical Center, Departments of Environmental Medicine and Microbiology & Immunology. Rochester, NY 14642, USA.
Gary H PerdewPennsylvania State University, University Park, PA 16802, USA.
David H SherrBoston University, School of Public Health, Boston, MA 02118, USA.
Heike WeighardtUniversity of Bonn, Life&Medical Scienes (LIMES) Institute, 53115 Bonn, Germany.
Katharina M RolfesIUF - Leibniz Research Institute for Environmental Medicine Auf́m Hennekamp, 50 40225 Düsseldorf Germany.
Charlotte EsserIUF - Leibniz Research Institute for Environmental Medicine Auf́m Hennekamp, 50 40225 Düsseldorf Germany. Electronic address: charlotte.esser@iuf-duesseldorf.de.

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Martha Susiarjo · 1985 to 2026
$42.8M
TCDD EFFECT ON T LYMPHOCYTE DIFFERENTIATIONR01ES004862 · NIEHS · UNIVERSITY OF ROCHESTER · PI LAWRENCE, B PAIGE · 1990 to 2020
$6.5M
Human Immunotoxicity of Developmental PCB ExposureR01ES030300 · NIEHS · UNIVERSITY OF ROCHESTER · PI JUSKO, TODD, LAWRENCE, B PAIGE · 2019 to 2024
$2.7M
Developmental immunotoxicity of PFASR01ES036197 · NIEHS · UNIVERSITY OF ROCHESTER · PI B Paige Lawrence · 2024 to 2026
$1.4M
NIEHS NIH HHS P30 ES001247NIEHS NIH HHS R01 ES004862NIEHS NIH HHS R01 ES030300NIEHS NIH HHS R01 ES036197
6 · The paper itself

Abstract

The ability to sense and process environmental cues is a fundamental aspect of an organism's biology. The evolutionary ancient transcription factor AHR (aryl hydrocarbon receptor) has evolved in animals to sense low molecular weight compounds derived from environmental exposure, dietary plants, the gut/skin microbiome, or generated endogenously from tryptophan upon ultraviolet light (UV) exposure or enzymatic catabolism. The binding of such molecules results in a cascade of events leading to the transcription of target genes. The AHR gene locus was first identified in mice in 1982. Since then, the beneficial and detrimental effects of AHR agonist-driven activation or lack thereof have been studied, particularly in relation to environmental chemical toxicity, carcinogenicity, or tissue homeostasis, e.g. barrier tissues. AHR ligands are also being considered as a potential new therapeutic class of molecules for the treatment of cancer, debilitating and chronic inflammatory diseases or metabolic disorders. A series of international meetings initiated twenty years ago have provided a comprehensive overview of AHR research. At the meeting in Düsseldorf in 2024, the identification of tailor-made ligands using modern, artificial intelligence (AI)-based approaches was a key topic of discussion, as were current attempts to resolve the dual nature of AHR activation - beneficial and harmful. While our understanding is still in its infancy, research was also presented that highlights previously unrecognized roles of the AHR in many diseases.

Indexed as

Basic Helix-Loop-Helix ProteinsCongresses as TopicReceptors, Aryl HydrocarbonSignal TransductionAnimalsHumansNeoplasmsAHR protein, humanBasic Helix-Loop-Helix ProteinsReceptors, Aryl HydrocarbonAryl Hydrocarbon ReceptorGene ExpressionHealth and diseaseInternational conferenceLigandsSignaling

Identifiers

PMID39983850
PMCPMC12802511

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.